Clinical trials: Obesity Type 2 Diabetes Mellitus
Obesity & Overweight, Type 2 Diabetes
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
- Trial name
- NCT07539415
- Testing
- DWRX5003, DWC202502, DWC202503
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
A Phase 1/2, multiple dose study with 6 cohorts of ascending doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT02548585
- Testing
- MEDI0382
- Where
- 11 sites in Germany
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
- Trial name
- NCT07399678
- Testing
- ALV-100
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alveus Therapeutics, Inc.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.
- Conditions
- Obesity, Overweight, Metabolism and Nutrition Disorder
- Trial name
- SURMOUNT-CN (NCT05024032)
- Testing
- Tirzepatide
- Where
- 29 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Obesity
Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND
In recent years, the global rise in obesity and type 2 diabetes has become a major public health issue. In New Caledonia, 38% of the adult population has a body mass index ≥30.
- Trial name
- MIND (NCT07205913)
- Testing
- 25 ml blood sample, Urine sample, Stools
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Overweight, Type 2 Diabetes
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
- Conditions
- Overweight, Type 2 Diabetes, Obesity
- Trial name
- NCT06926842
- Testing
- Petrelintide
- Where
- 48 sites in United States
- Volunteers
- 221 people
- Sponsor
- Zealand Pharma
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
- Trial name
- ENLIGHTEN-1 (NCT07321886)
- Testing
- Eloralintide
- Where
- 158 sites in United States, Argentina and 13 more
- Volunteers
- 1,980 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Overweight and Obesity
A Phase I Study of GZR18 Injection in Healthy Subjects
This trial is conducted in China. The aim of the trial is to evaluate the safety and tolerability of GZR18 injection in healthy subjects following single dose and once-weekly dose for 2 consecutive weeks until reaching the target…
- Trial name
- NCT06548997
- Testing
- GZR18
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- Lenbelintide
- Where
- 220 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Weight Management, Treatment Of Obesity
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes
- Trial name
- NCT00542009
- Testing
- CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD
- Where
- 54 sites in United States, Bulgaria and 5 more
- Volunteers
- 252 people
- Sponsor
- Pfizer
Type 2 Diabetes, Obesity
Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner
The purpose of this study is to evaluate EndoBarrier Gastrointestinal Liner in the post marketing environment in subjects who are obese and have Type 2 Diabetes.
- Trial name
- NCT01114438
- Testing
- EndoBarrier Gastrointestinal Liner
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Morphic Medical Inc.
Obesity
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part…
- Trial name
- NCT06700538
- Testing
- ARO-INHBE, Tirzepatide
- Where
- 15 sites in Australia, Canada and 2 more
- Volunteers
- 190 people
- Sponsor
- Arrowhead Pharmaceuticals
Diabetes, Obesity
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in…
- Trial name
- NCT04617275
- Testing
- PF-06882961
- Where
- 38 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer
Overweight, Diabetes Mellitus Type 2 in Obese
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187
Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187 It will be conducted in three parts, as described below: Part I will be the Single…
- Trial name
- NCT01874366
- Testing
- P11187
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Piramal Enterprises Limited
Type 2 Diabetes (T2DM)
A Study of BGM0504 in Early T2DM With Obesity
This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise.
- Trial name
- NCT07743983
- Testing
- BGM0504, semaglutide
- Where
- China
- Volunteers
- 372 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obese, Obesity
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index [BMI] ≥ 30 kg/m2) or overweight (BMI…
- Conditions
- Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
- Trial name
- GSBR-1290 (NCT07400588)
- Testing
- Aleniglipron
- Where
- 16 sites in United States
- Volunteers
- 58 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Obesity, Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy
The purpose of this study is to compare the effectiveness and safety of topiramate with placebo in the treatment of obesity and Type 2 diabetes mellitus in patients who have failed on sulfonylurea therapy.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231634
- Testing
- topiramate
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in…
- Trial name
- NCT00042601
- Testing
- Pramlintide acetate
- Where
- Australia
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Healthy, Overweight
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits.
- Conditions
- Healthy, Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT06945419
- Testing
- LY4086940
- Where
- 5 sites in United States, Singapore
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company